Archives
-
AAPH: Controlled Oxidative Stress in Research
2026-09-23
AAPH is a water-soluble radical initiator used to create reproducible oxidative stress in erythrocyte and other in vitro assays. It can model oxidative damage, but it is not a selective ferroptosis inducer or a substitute for testing PRDX6–GPX4 biology directly.
-
Chloroquine Research Workflows & Troubleshooting
2026-09-23
Build more reliable autophagy, immune-signaling, cancer, malaria, and antiviral assays with Chloroquine BA1002. This guide separates lysosomal flux effects from nonspecific toxicity and translates evidence from cell culture, animal models, and clinical observations into practical experimental decisions.
-
MDockPeP2_VS for Peptide Inhibitor Discovery
2026-09-22
The 2024 PNAS Nexus study introduces MDockPeP2_VS, an automated structure-based platform that narrows peptide conformational searches by combining molecular docking with structural conservation between protein folding and protein–peptide binding. Applied to TEM-1 β-lactamase, the workflow identified peptide TF7 as a functional inhibitor with a reported Ki of 1.37 ± 0.37 μM, providing a practical computational route for early β-lactamase inhibitor discovery.
-
Caspase-3 Colorimetric Assay Kit Guide
2026-09-22
The Caspase-3 Colorimetric Assay Kit provides a practical way to measure DEVD-dependent caspase-3 activity through p-nitroaniline release and absorbance detection. It is suitable for comparative apoptosis studies and related biochemical workflows, but it should not be treated as a standalone proof of apoptosis, caspase-3 identity, or disease-specific mechanism.
-
Clozapine N-oxide for Circuit-Level Neuroscience
2026-09-21
Clozapine N-oxide enables reversible DREADD-based control of defined neural pathways, making it useful for linking circuit activity with behavior and synaptic physiology. This practical guide translates an ACC–vCA1 Alzheimer disease study into an actionable CNO workflow, with preparation, assay design, and troubleshooting guidance.
-
A-1210477: MCL-1 Inhibitor Workflow Guide
2026-09-21
Build cleaner mitochondrial apoptosis experiments with A-1210477, a selective MCL-1 inhibitor suited to separating MCL-1 dependence from nonspecific cytotoxicity. This guide covers stock preparation, dose–response design, BAX/BAK-centered validation, combination studies, and practical troubleshooting.
-
Arachidonic Acid Accelerates Vaccine Humoral Immunity
2026-09-20
The reference study shows that dietary arachidonic acid (ARA) can accelerate and strengthen rabies vaccine-induced neutralizing antibody responses in mice and human volunteers. Its central mechanistic contribution is linking lymph-node ARA metabolism to prostaglandin I2, cAMP-PKA signaling, CD86 expression, and B-cell activation-induced cytidine deaminase.
-
EX 527 SIRT1 Inhibition for Bone Assays
2026-09-19
EX 527 (SEN0014196) enables selective SIRT1 loss-of-function studies spanning p53 acetylation, DNA damage responses, endothelial activity, and osteogenic differentiation. Its strong preference for SIRT1 over SIRT2 and SIRT3 makes it useful for separating SIRT1-dependent phenotypes from broader sirtuin effects.
-
Chloroquine BA1002: Mechanism & Research
2026-09-18
Chloroquine is a 4-aminoquinoline research compound that raises lysosomal pH, inhibits autophagic flux, and modulates endosomal immune signaling. Its preclinical anticancer and antiviral findings are context-dependent, while CYP-mediated metabolism and cardiovascular toxicity limit direct translation to clinical use.
-
GZMK+ CD8+ T Cells Drive Recurrent Airway Inflammation
2026-09-18
This Nature study identifies persistent GZMK-expressing CD8+ memory T-cell clones as cellular drivers of recurrent nasal polyps and airway inflammation. By integrating T-cell receptor sequencing, single-cell profiling, human tissue analysis, and mouse asthma experiments, the authors connect GZMK proteolysis to complement activation and show that targeting this pathway can reduce established disease.
-
ADRA2A Activation Sensitizes Ovarian Cancer to Carboplatin
2026-09-17
Albanna and colleagues used an unbiased repurposing screen to identify ADRA2A agonism as a pharmacological route for increasing carboplatin sensitivity in ovarian cancer cell models. Validation with three agonists, multiple cell lines, independent viability assays, and ADRA2A overexpression supports a target-centered hypothesis, while remaining preclinical and in vitro.
-
Atorvastatin: Designing Mechanism-First Assays
2026-09-17
Atorvastatin is more than an HMG-CoA reductase inhibitor: it is a mechanistic probe connecting mevalonate flux, vascular signaling, and ferroptosis. This guide translates recent hepatocellular carcinoma evidence into assay-design decisions, controls, and interpretation strategies.
-
EZ Cap EGFP mRNA 5-moUTP: Applied Workflow
2026-09-16
Use this enhanced green fluorescent protein mRNA as a practical benchmark for delivery, translation, viability, and imaging experiments. Its Cap 1 structure, 5-moUTP modification, and approximately 100-nucleotide poly(A) tail support a controlled way to compare formulations before advancing to therapeutic or functional mRNA cargos.
-
ICAA Disrupts HBV Replication via HO-1 and ROS
2026-09-16
The reference study shows that isochlorogenic acid A (ICAA) suppresses hepatitis B virus replication through multiple effects involving HO-1-associated ROS modulation, reduced viral nucleic acids, and defective particle morphogenesis. Its integrated cellular and particle-level design provides a framework for separating effects on cccDNA-linked replication from defects in capsid formation and envelopment.
-
Iterative Discovery of TAS2R14 Ligands
2026-09-15
The reference study presents an iterative experimental–computational strategy for finding agonists and antagonists of TAS2R14, a highly promiscuous bitter taste GPCR without an experimental structure. By combining cell-based screening, synthesis of flufenamic acid derivatives, and progressive binding-pocket refinement, the authors substantially expand the chemical toolkit available for studying this receptor.